<DOC>
	<DOCNO>NCT02723955</DOCNO>
	<brief_summary>GSK3359609 anti-Inducible T cell Co-Stimulator ( ICOS ) receptor agonist antibody intend treatment cancer different histology . This first-time-in-human ( FTIH ) , open-label . multicenter study design investigate safety , pharmacology , preliminary antitumor activity subject advance recurrent solid tumor aim establish recommend dose ( ) GSK3359609 exploration monotherapy combination pembrolizumab immune therapy . The study comprise two primary part , compose two phase : Part 1 : GSK3359609 monotherapy Part 1A dose escalation phase Part 1B dose expansion phase ; Part 2 : GSK3359609 combination therapy Part 2A dose escalation phase Part 2B dose expansion phase . Each part phase study include screening period , treatment period , follow-up period . The primary objective study determine safety , tolerability , maximum tolerate dose maximum administer dose GSK3359609 alone combination .</brief_summary>
	<brief_title>Dose Escalation Expansion Study GSK3359609 Subjects With Selected Advanced Solid Tumors ( INDUCE-1 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion Criteria Capable give sign , write informed consent Male female , age &gt; =18 year ( time consent obtain ) . Histological cytological documentation invasive carcinoma diagnose locally advanced/metastatic recurrent one follow tumor type : bladder ; cervical ; colorectal ( include appendix ) ; esophagus , squamous cell ; head neck ; melanoma ; malignant pleural mesothelioma ( MPM ) ; nonsmallcell lung cancer ( NSCLC ) prostate Disease progress standard therapy specific tumor type , standard therapy proven ineffective , intolerable , consider inappropriate , standard therapy exists . Subjects receive 5 prior line therapy advance disease include standard care investigational therapy . Archival tumor tissue obtain anytime initial diagnosis study entry ; fresh tumor biopsy require archival tissue unavailable . Agree undergo pretreatment treatment biopsy disease amenable biopsy require PK/pharmacodynamic dose expansion cohort . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Palpable lesion measurable radiographic photographic evaluation may utilize measurable lesion . Any measurable lesion biopsied Screening follow target/index lesion . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 Life expectancy least 12 week . Adequate organ function QTcF &lt; 450 millisecond ( msec ) QTcF &lt; 480 msec subject bundle branch block . The QTcF QT interval correct heart rate accord Fridericia 's formula , machineread manually overread . A female subject eligible participate pregnant ( confirm negative serum betahuman chorionic gonadotrophin [ betahCG ] test ) females reproductive potential ) , lactate reproductive potential agrees follow one option list protocol 30 day prior first dose study medication 120 day last dose study treatment . Male subject female partner child bear potential must agree use one method contraception specify protocol time first dose study treatment 120 day last dose study treatment . Exclusion Criteria Prior treatment follow therapy ( last dose prior treatment first dose GSK3359609 ) : Anticancer therapy within 30 day 5 half life drug , whichever short . At least 14 day must elapse last dose prior anticancer agent first dose study drug administer . Prior radiation therapy : permissible least one nonirradiated measurable lesion available assessment accord RECIST version 1.1 solitary measurable lesion irradiate , objective progression document . A wash least two week start study drug radiation intend use extremities bone metastases 4 week radiation chest , brain , visceral organ require . Investigational therapy within 30 day 5 halflives investigational product ( whichever shorter ) . At least 14 day must elapse last dose investigational agent first dose study drug administer . Prior allogeneic autologous bone marrow transplantation solid organ transplantation . Toxicity previous anticancer treatment Invasive malignancy history invasive malignancy disease study Central nervous system ( CNS ) metastases , follow exception : Subjects previouslytreated CNS metastasis , asymptomatic , requirement steroid least 14 day prior first dose study drug . Note : Subjects carcinomatous meningitis exclude regardless clinical stability . Received transfusion blood product ( include platelet red blood cell ) administration colony stimulate factor ( include granulocyte colonystimulating factor [ GCSF ] , granulocytemacrophage colonystimulating factor , recombinant erythropoietin ) within 14 day prior first dose GSK3359609 . Major surgery &lt; =4 week first dose study treatment . Subjects must also fully recover surgery ( major minor ) and/or complication initiate study treatment . Active autoimmune disease require systemic treatment within last two year ( i.e. , use disease modify agent , corticosteroid immunosuppressive drug ) . â€¢ Note : Replacement therapy ( e.g. , thyroxine physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Concurrent medical condition require use systemic immunosuppressive medication within 7 day first dose study treatment . Physiologic dose corticosteroid treatment endocrinopathies steroids minimal systemic absorption , include topical , inhaled , intranasal corticosteroid may continue subject stable dose . Active infection require systemic therapy , know human immunodeficiency virus infection , positive test hepatitis B hepatitis C. Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone , liver metastasis , otherwise stable chronic liver disease per investigator assessment ) . Recent history ( within past 6 month ) acute diverticulitis , inflammatory bowel disease , intraabdominal abscess , gastrointestinal obstruction Receipt live vaccine within 4 week . Recent history allergen desensitization therapy within 4 week start study treatment . History severe hypersensitivity monoclonal antibody . History evidence cardiac abnormality History ( current past ) idiopathic pulmonary fibrosis , pneumonitis ( past pneumonitis exclusion steroid require treatment ) , interstitial lung disease , organize pneumonia . Note : postradiation change lung relate prior radiotherapy and/or asymptomatic radiationinduced pneumonitis require treatment may permit agree investigator Medical Monitor . Recent history ( within 6 month ) uncontrolled symptomatic ascites pleural effusion . Any serious and/or unstable preexist medical , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ICOS receptor agonist antibody</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>KEYNOTE-478</keyword>
	<keyword>GSK3359609</keyword>
	<keyword>Dose expansion</keyword>
	<keyword>Dose escalation</keyword>
</DOC>